KR101383228B1 - A3 아데노신 수용체 알로스테릭 조절제 - Google Patents

A3 아데노신 수용체 알로스테릭 조절제 Download PDF

Info

Publication number
KR101383228B1
KR101383228B1 KR1020087020924A KR20087020924A KR101383228B1 KR 101383228 B1 KR101383228 B1 KR 101383228B1 KR 1020087020924 A KR1020087020924 A KR 1020087020924A KR 20087020924 A KR20087020924 A KR 20087020924A KR 101383228 B1 KR101383228 B1 KR 101383228B1
Authority
KR
South Korea
Prior art keywords
imidazo
quinolin
amine
phenyl
cyclopentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020087020924A
Other languages
English (en)
Korean (ko)
Other versions
KR20080099855A (ko
Inventor
애니코 고블요스
조한스 브루세.
아드리안 피 이저만
장쭈오 가오
케네시 제이콥슨
Original Assignee
더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈
유니버시타이트 라이덴
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈, 유니버시타이트 라이덴 filed Critical 더 가번먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 레프리젠티드 바이 더 세크러터리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비스즈
Publication of KR20080099855A publication Critical patent/KR20080099855A/ko
Application granted granted Critical
Publication of KR101383228B1 publication Critical patent/KR101383228B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
KR1020087020924A 2006-01-26 2007-01-25 A3 아데노신 수용체 알로스테릭 조절제 Active KR101383228B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76214106P 2006-01-26 2006-01-26
US60/762,141 2006-01-26
PCT/US2007/001930 WO2007089507A1 (en) 2006-01-26 2007-01-25 A3 adenosine receptor allosteric modulators

Publications (2)

Publication Number Publication Date
KR20080099855A KR20080099855A (ko) 2008-11-13
KR101383228B1 true KR101383228B1 (ko) 2014-04-09

Family

ID=38116104

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087020924A Active KR101383228B1 (ko) 2006-01-26 2007-01-25 A3 아데노신 수용체 알로스테릭 조절제

Country Status (10)

Country Link
US (2) US8420664B2 (cg-RX-API-DMAC7.html)
EP (1) EP1983990B1 (cg-RX-API-DMAC7.html)
JP (2) JP5414277B2 (cg-RX-API-DMAC7.html)
KR (1) KR101383228B1 (cg-RX-API-DMAC7.html)
CN (1) CN101410114B (cg-RX-API-DMAC7.html)
AT (1) ATE502640T1 (cg-RX-API-DMAC7.html)
DE (1) DE602007013359D1 (cg-RX-API-DMAC7.html)
DK (1) DK1983990T3 (cg-RX-API-DMAC7.html)
ES (1) ES2360632T3 (cg-RX-API-DMAC7.html)
WO (1) WO2007089507A1 (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
US7906518B2 (en) * 2006-06-27 2011-03-15 Cbt Development Limited Therapeutic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
JP2010508835A (ja) * 2006-11-10 2010-03-25 ノバルティス アーゲー シクロペンテンジオールモノアセテート誘導体
US20110144156A1 (en) * 2008-08-19 2011-06-16 Universiteit Leiden A3 adenosine receptor allosteric modulators
WO2010134067A1 (en) * 2009-05-17 2010-11-25 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
MX378538B (es) * 2012-08-09 2025-03-10 Can Fite Biopharma Ltd Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual.
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
EP3445761A1 (en) * 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
ES2676535B1 (es) 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
IL254535A0 (en) 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
EP4499641A1 (en) * 2022-03-29 2025-02-05 The United States of America, as represented by the Secretary, Department of Health and Human Services A3 adenosine receptor positive allosteric modulators
WO2024014851A1 (ko) * 2022-07-12 2024-01-18 주식회사 넥스트젠바이오사이언스 Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물
IL300132A (en) * 2023-01-23 2024-08-01 Can Fite Biopharma Ltd Pancreatic cancer treatment
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR960007566A (ko) 1994-08-19 1996-03-22 김정규 신규한 퀴놀릴아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도
KR20010030891A (ko) * 1997-10-03 2001-04-16 마크로메드 인코퍼레이션 가역적 열 겔화 성질을 갖는 생분해성 저분자량 트리블럭폴리(락티드-코-글리콜리드) 폴리에틸렌 글리콜 공중합체
WO2002062801A1 (en) * 2001-02-05 2002-08-15 Otsuka Pharmaceutical Factory, Inc. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
US20020179549A1 (en) * 2001-06-04 2002-12-05 Chris Felcman System and method for mounting a keyboard and display assembly in a 1U rack space
US20040137477A1 (en) * 2002-10-22 2004-07-15 Can-Fite Biopharma, Ltd. A3AR as a marker for a diseased state
EP1699459B1 (en) 2003-12-29 2007-06-06 Can-Fite Biopharma Ltd. Method for treatment of multiple sclerosis
CN101083998A (zh) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 用腺苷a3受体激动剂强化治疗hif-1介导的病症
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Mol. Pharmacol., Vol. 62, pp. 81-89(2002) *
Mol. Pharmacol., Vol. 62, pp. 81-89(2002)*

Also Published As

Publication number Publication date
JP2013253108A (ja) 2013-12-19
DK1983990T3 (da) 2011-07-11
JP2009524668A (ja) 2009-07-02
WO2007089507A1 (en) 2007-08-09
US20090054476A1 (en) 2009-02-26
EP1983990A1 (en) 2008-10-29
JP5414277B2 (ja) 2014-02-12
CN101410114B (zh) 2012-07-04
US8420664B2 (en) 2013-04-16
US9326978B2 (en) 2016-05-03
ATE502640T1 (de) 2011-04-15
DE602007013359D1 (de) 2011-05-05
KR20080099855A (ko) 2008-11-13
US20130197025A1 (en) 2013-08-01
CN101410114A (zh) 2009-04-15
ES2360632T3 (es) 2011-06-07
EP1983990B1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
KR20080099855A (ko) A3 아데노신 수용체 알로스테릭 조절제
TWI615393B (zh) 丙烯酸類衍生物、其製備方法及其在醫藥上的用途
CN105175394B (zh) 具有抗癌活性的化合物
EP1650203B1 (en) Process of preparation of benzimidazol-2-yl quinolinone derivatives
US20030069248A1 (en) Quinazoline derivatives as medicaments
WO2018205938A1 (zh) Parp抑制剂、其药物组合物、制备方法和应用
TW201936596A (zh) Tlr7/8拮抗劑及其用途
AU2019233207B2 (en) Heteroaryl compounds as kinase inhibitor
CN103224496B (zh) 三环类PI3K和/或mTOR抑制剂
BR112013004613B1 (pt) Imidazo[4,5-c]quinolinas como inibidores de dna-pk, seus intermediários e seu processo de preparação, e composição farmacêutica
CN116997339A (zh) 作为治疗剂的cGAS活性抑制剂
KR20210038906A (ko) 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제
JP7092742B2 (ja) ケモカインの生物活性を中和するためのピリミジノン誘導体およびその使用
JP2025541823A (ja) Dnaポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用
TW200539868A (en) Novel 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
EP3661935A1 (en) Substituted pyrazolopyrimidines useful as kinases inhibitors
KR20180085814A (ko) 치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법
ES2422872T3 (es) Moduladores alostéricos del receptor de adenosina A3
CN107501279B (zh) 呋喃并喹啉二酮类化合物及其医药用途
CN107141287B (zh) 2-亚胺-5-酮基-2,5-二氢-1-h-二吡啶并嘧啶类化合物
JP2023509845A (ja) 金属塩及びその使用
JP2021527071A (ja) Epac阻害剤としてのチエノ[2,3−b]ピリジン誘導体及びその医薬用途
JP2009543801A (ja) 神経障害処置におけるトリフルオロメチル置換ベンズアミドの使用
WO2023046214A1 (zh) 一种受体相互作用蛋白激酶1的抑制剂及其制备方法、应用
JP2008526817A (ja) 新規のピロロジヒドロイソキノリン

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080826

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120109

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130821

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20140227

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20140402

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20140403

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20170323

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20170323

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20190403

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20190403

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20200401

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20220329

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20240319

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20250317

Start annual number: 12

End annual number: 12